Drugs / ISIS EIF4E Rx
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01234025 | Nov 2010 → May 2013 | castration-resistant prostate carcinoma | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01234038 | Nov 2010 → Oct 2012 | non-small cell lung carcinoma | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS EIF4E Rx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01234038 ↗ |
| Known as | ISIS 183750 | “A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer” NCT01234025 ↗ |
| Action | Inhibit | “an eIF4E Inhibitor” NCT01234025 ↗ |
| Route | Intravenous | “administered as a 3-hour intravenous infusion” NCT01234025 ↗ |